Repare Therapeutics Inc.
CIK 0001808158
Revenue (TTM)
—
Q3 Oct 2025
Net Income (TTM)
−$77.94M
+9.7% YoY
Q3 Oct 2025
EPS Diluted (TTM)
−$1.83
+10.3% YoY
Q3 Oct 2025
Gross Margin
—
Q3 Oct 2025
Operating Margin
—
Q3 Oct 2025
Net Margin
—
Q3 Oct 2025
Free Cash Flow (TTM)
−$80.73M
Q3 Oct 2025
Cash
$72.83M
Q3 Oct 2025
Total Debt
—
Q3 Oct 2025
Shares Outstanding
42.99M sh
Q3 Oct 2025
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.